OpGen, Inc. Stock News

The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above market estimates of 5.5%. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. OpGen The Trade: OpGen, Inc. (NASDAQ: OPGN ) Chief Operating Officer Johannes Bacher acquired a total of 25,000 shares at an average price of $0.85. To acquire these shares, it cost $21.25 thousand. Whats Happening: OpGen recently said it sees preliminary FY21 sales of $4.3 million. What OpGen Does: OpGen Inc is a precision Full story available on Benzinga.com

ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat i

ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat inf

OpGen (OPGN) announces preliminary revenue for in 2021 of ~$4.3M (consensus $3.8M), compared to ~$4.2M in 2020.Preliminary revenue for Q4 2021 was ~$1.4M (consensus $0.9M), despite

ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help comb

OpGen Inc. (NASDAQ:OPGN) traded at $1.05 at close of the session on Monday, 12/20/21, made a downward move of -2.78% on its previous days price. Looking at the stock we see that its previous close was $1.08 and the beta (5Y monthly) reads -0.61 with the days price range being $1.02 $1.08. In terms OpGen Inc. (NASDAQ:OPGN) Slides -2.78 Percent In Recent Trade, What Can We Expect Next? Read More »

OpGen Inc. (NASDAQ:OPGN) shares, rose in value on Thursday, 12/16/21, with the stock price down by -9.84% to the previous days close as strong demand from buyers drove the stock to $1.10. Actively observing the price movement in the last trading, the stock closed the session at $1.22, falling within a range of $1.10 and OpGen Inc. (NASDAQ: OPGN) Does It Provide Stability And Growth? Read More »

During the last session, OpGen Inc. (NASDAQ:OPGN)s traded shares were 1.72 million, with the beta value of the company hitting -0.77. At the end of the trading day, the stocks price was $1.22, reflecting an intraday loss of -3.17% or -$0.04. The 52-week high for the OPGN share is $4.37, that puts it down -258.2 Given A -258.2% Drop From High, Can OpGen Inc. (NASDAQ: OPGN) Quickly Recover? Read More »

OpGen, Inc. (NASDAQ:OPGN) with the stream of -3.17% also noticed, India ShiftPixy, Inc. (NASDAQ:PIXY) encountered a rapid change of -1.49% in the last hour of Wednesdays trading session. OpGen, Inc. The post Golden Stock: OpGen, Inc. (NASDAQ:OPGN), ShiftPixy, Inc. (NASDAQ:PIXY) appeared first on Stocks Equity .

ROCKVILLE, Md., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informa

ROCKVILLE, Md., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (Ares), has successfully completed Phase 1 of its collaboration with a leading U.S. CRO and reference lab, originally announced in August . During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informa

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, OpGen or the Company), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that stockholders have approved the two proposals voted on at the Companys Special Meeting of Stockholders held on December 8, 2021.

Northern Trust Corp grew its position in OpGen, Inc. (NASDAQ:OPGN) by 71.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 72,108 shares of the medical research companys stock after buying an additional 30,065 shares during the quarter. Northern Trust Corps holdings in OpGen []

ROCKVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat i